Elamipretide is a mitochondria-targeted tetrapeptide developed to treat diseases caused by mitochondrial dysfunction, including primary mitochondrial myopathy, Barth syndrome, and heart failure.
Elamipretide is a mitochondria-targeted tetrapeptide developed to treat diseases caused by mitochondrial dysfunction, including primary mitochondrial myopathy, Barth syndrome, and heart failure.
Mechanism & Research
Elamipretide selectively targets cardiolipin in the inner mitochondrial membrane, improving:
Mitochondrial Bioenergetics
ATP Production
Cellular Respiration & Organ Function
It has shown potential to restore mitochondrial structure, reduce oxidative stress, and improve muscle and cardiac performance in both clinical and preclinical studies.
Frequently Asked Questions
Q1: What is Elamipretide API?
Elamipretide is a mitochondria-targeted tetrapeptide designed to treat various medical conditions resulting from mitochondrial dysfunction.
Q2: What diseases can Elamipretide help treat?
It is developed for the treatment of diseases caused by mitochondrial dysfunction, such as primary mitochondrial myopathy, Barth syndrome, and heart failure.
Q3: How does Elamipretide function at the cellular level?
Elamipretide selectively targets cardiolipin within the inner mitochondrial membrane to support and enhance mitochondrial health.
Q4: What key improvements does Elamipretide offer to mitochondria?
It improves mitochondrial bioenergetics, enhances ATP production, and supports cellular respiration and overall organ function.
Q5: What benefits have been observed in research studies?
Clinical and preclinical studies indicate its potential to restore mitochondrial structure, lower oxidative stress, and improve both muscle and cardiac performance.
